Prosecution Insights
Last updated: November 04, 2026

B'Okcares Ltd.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

B'Okcares Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. Prosecution is concentrated under 1 distinct examiner and 1 distinct art unit. BAEK, JONGHWAN NMN is the busiest examiner, with 1 busiest examiner pending office action currently assigned. The company's 1 pending office action is the sole focus of its current patent office activity. By working with only 1 distinct examiner, the applicant can tailor its responses to the specific feedback of BAEK, JONGHWAN NMN.

This concentration in 1 distinct art unit simplifies the administrative burden but concentrates the risk of the prosecution on a single examiner's decision. The 1 busiest examiner pending action represents the entirety of the current pipeline. Practitioners should note that having 1 distinct examiner means there is no opportunity to compare examination styles within the portfolio. The focus on the Biotechnology & Pharmaceuticals field suggests that the company's current research and development are highly specialized. Successfully resolving the 1 pending office action is the immediate priority for securing the company's intellectual property rights.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BAEK, JONGHWAN NMN 1 50.0% +0.0%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18207184 Homeopathic mixture for relieving general fatigue symptoms and cancer treatment related fatigue symptoms BAEK, JONGHWAN NMN —

Top Art Units

Art UnitApps
1618 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18207184 Homeopathic mixture for relieving general fatigue symptoms and cancer treatment related fatigue symptoms BAEK, JONGHWAN NMN 1618 §103§112 Final Rejection — Pending Jun 08, 2023

Managing B'Okcares Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does B'Okcares Ltd. have?

B'Okcares Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most B'Okcares Ltd. applications?

Jonghwan Nmn Baek has the most, with 1 of B'Okcares Ltd.'s pending office actions.

What technology area are B'Okcares Ltd.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month